Oncology Studies from an IRB Perspective
IRB Chair Rebecca Rogers will discuss IRB review of oncology studies, paying particular attention to recent innovations in oncology research and how they may impact the IRB’s review.
The industry’s choice for
central and local IRB services.
By combining quality reviews with global consulting services, uniquely responsive client service and proprietary, Part 11 compliant technology tools, we are able to both improve human subject protection and allow our clients to reach their business goals.
We've been serving the clinical trial industry since 1983.
Our technology tools deliver unparalleled visibility and efficiency.
We complete thorough, ethical reviews as swiftly as possible.
The Schulman IRB Webinar Series offers timely information to study sponsors, CRO representatives, investigators and institutional personnel in an engaging, easy-to-parse format.
CLICK HERE to see our full webinar archive, as well as to register for upcoming sessions.
Schulman IRB is proud to be a platinum partner of the 2016 MAGI East Clinical Research Conference in Boston, Massachusetts.Read More
In response to client feedback, Schulman IRB is changing its informed consent (IC) version control format. Schulman IC versions will shift from a date (e.g., January 1, 2016) to a number (e.g., 1.0) for all new studies submitted on or after May 2, 2016.Read More
Sharon Nelson, MSN, RN, CNS, CIP, executive director of consulting and compliance services at Schulman IRB shares her experiences and insight in the research ethics field.Read More
The NPRM outlines changes to the existing federal policy protecting human subjects – the “Common Rule.”Read More